[go: up one dir, main page]

WO2007039781A3 - Nouveaux composes - Google Patents

Nouveaux composes Download PDF

Info

Publication number
WO2007039781A3
WO2007039781A3 PCT/HU2006/000087 HU2006000087W WO2007039781A3 WO 2007039781 A3 WO2007039781 A3 WO 2007039781A3 HU 2006000087 W HU2006000087 W HU 2006000087W WO 2007039781 A3 WO2007039781 A3 WO 2007039781A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
compounds
oxadioi
clutamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2006/000087
Other languages
English (en)
Other versions
WO2007039781A2 (fr
Inventor
Krisztina GÁL
Csaba WÉBER
Gábor András WÁGNER
Attila HORVÁTH
Györgyné NYÉKI
Mónika VASTAG
György KESERÜ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Vegyeszeti Gyar Nyrt
Original Assignee
Richter Gedeon Vegyeszeti Gyar RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszeti Gyar RT filed Critical Richter Gedeon Vegyeszeti Gyar RT
Publication of WO2007039781A2 publication Critical patent/WO2007039781A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007039781A3 publication Critical patent/WO2007039781A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés de formule (I) dans laquelle Y1 et Y2 sont sélectionnés dans le groupe constitué par hydrogène, atome halogène; C1-4 alkyle, C1-4 alkoxy, cyano et un groupe trifluorométhyle, Q représente le groupe -CH- ou N; X1 et X2 sont différents et sont sélectionnés indépendamment dans le groupe N et O; Z désigne le groupe -(CH2)n- ou S; n est égal à 1 ou à 2; R est sélectionné dans le groupe constitué par C1-7 alkyle, C1-4 haloalkyle, C1-4 hydroxyalkyle, C1-4 cyanoalkyle, C1-3 OC1-3 alkyle, C2-7 alcényle, C2-7 alkynyle, C0-2(NR1R2)alkyle éventuellement substitués; par un cycloalkyle éventuellement substitué en C3-7, aryle, hétéroaryle ou hétérocyclyle saturés; R1 et R2 sont sélectionnés indépendamment dans le groupe constitué par hydrogène, C1-7 alkyle ou C1-6 alkanoyle; par des énantiomères et/ou des racémates et/ou des diastéréoisomères et/ou des isomères géométriques et/ou des sels pharmaceutiquement acceptables formés d'acides et de bases; l'invention concerne également des procédés de production desdits composés, des compositions pharmaceutiques renfermant lesdits composés et leur utilisation dans la prévention et/ou le traitement de troubles induits par le récepteur de mGluR5.
PCT/HU2006/000087 2005-10-05 2006-10-05 Nouveaux composes Ceased WO2007039781A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP0500920 2005-10-05
HU0500920A HUP0500920A2 (en) 2005-10-05 2005-10-05 Oxadiazole derivatives, process for their preparation and their use

Publications (2)

Publication Number Publication Date
WO2007039781A2 WO2007039781A2 (fr) 2007-04-12
WO2007039781A3 true WO2007039781A3 (fr) 2010-08-26

Family

ID=89986317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2006/000087 Ceased WO2007039781A2 (fr) 2005-10-05 2006-10-05 Nouveaux composes

Country Status (2)

Country Link
HU (1) HUP0500920A2 (fr)
WO (1) WO2007039781A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007334436A1 (en) 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2421370A4 (fr) * 2009-04-23 2012-12-12 Merck Sharp & Dohme Modulateurs du récepteur mglur5 fourrés de 2-alkyl pipéridines
WO2011020116A1 (fr) 2009-08-14 2011-02-17 University Of Virginia Patent Foundation Imidamides inhibiteurs de sphingosine kinase
JP5775094B2 (ja) * 2009-12-29 2015-09-09 イーライ リリー アンド カンパニー 統合失調症の処置に有用な選択的ｍＧｌｕ５受容体増強因子としてのテトラヒドロトリアゾロピリジン化合物
WO2011092290A1 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de pyrazolo[5,1-b] utilisés en tant qu'antagonistes du récepteur de crf-1
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
CN103313977B (zh) * 2010-10-21 2015-06-03 拜耳知识产权有限责任公司 1-(杂环羰基)哌啶
JP5814491B2 (ja) 2012-06-04 2015-11-17 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ベンズイミダゾール−プロリン誘導体
WO2014057435A1 (fr) * 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Antagonistes des récepteurs de l'orexine, qui sont des dérivés [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone
JP2016510810A (ja) 2013-03-12 2016-04-11 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体
LT3077391T (lt) 2013-12-04 2018-10-25 Idorsia Pharmaceuticals Ltd Benzimidazolo prolino darinių panaudojimas
US20220089581A1 (en) * 2019-01-25 2022-03-24 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
MX2022003494A (es) * 2019-10-17 2022-04-25 Givaudan Sa Azacilos sustituidos como moduladores del miembro 8 de melastatina de potencial receptor transitorio (trmp8).
GB202012170D0 (en) * 2020-08-05 2020-09-16 Givaudan Sa Organic compounds
WO2022056042A1 (fr) * 2020-09-09 2022-03-17 University Of Virginia Patent Foundation Inhibiteurs de l'homologue de spinster 2 (spns2) à utiliser en thérapie

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017652A1 (fr) * 1996-10-18 1998-04-30 Boehringer Ingelheim Pharma Kg Oxadiazoles, procedes permettant de les preparer et leur utilisation comme medicaments
WO2000039125A1 (fr) * 1998-12-23 2000-07-06 Pfizer Limited Piperidines utilises comme modulateurs de ccr5
WO2002092086A1 (fr) * 2001-03-27 2002-11-21 F. Hoffmann-La Roche Ag Derives d'imidazo (1,2-a)-pyridine tenant lieu d'antagonistes mglur5
WO2004014902A2 (fr) * 2002-08-09 2004-02-19 Astrazeneca Ab Nouveaux composes
WO2005044797A1 (fr) * 2003-11-06 2005-05-19 Addex Pharmaceuticals Sa Modulateurs allosteriques de recepteurs glutamate metabotropiques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017652A1 (fr) * 1996-10-18 1998-04-30 Boehringer Ingelheim Pharma Kg Oxadiazoles, procedes permettant de les preparer et leur utilisation comme medicaments
WO2000039125A1 (fr) * 1998-12-23 2000-07-06 Pfizer Limited Piperidines utilises comme modulateurs de ccr5
WO2002092086A1 (fr) * 2001-03-27 2002-11-21 F. Hoffmann-La Roche Ag Derives d'imidazo (1,2-a)-pyridine tenant lieu d'antagonistes mglur5
WO2004014902A2 (fr) * 2002-08-09 2004-02-19 Astrazeneca Ab Nouveaux composes
WO2005044797A1 (fr) * 2003-11-06 2005-05-19 Addex Pharmaceuticals Sa Modulateurs allosteriques de recepteurs glutamate metabotropiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BING YAN ET AL.: "Quality control on combinatorial chemistry:", JOURNAL OF COMBINATORIAL CHEMISTRY, vol. 5, no. 5, 2003, pages 547 - 559, XP002413033 *

Also Published As

Publication number Publication date
HU0500920D0 (en) 2005-12-28
WO2007039781A2 (fr) 2007-04-12
HUP0500920A2 (en) 2007-07-30

Similar Documents

Publication Publication Date Title
WO2007039781A3 (fr) Nouveaux composes
HRP20140975T1 (hr) Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
EP1857457A3 (fr) Dérivé de benzimidazole et son utilisation comme antagoniste du récepteur AII
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
RU2010126105A (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
CA2523261A1 (fr) Derives de pyrimidine fusionnees a activite crf
JP2008526999A5 (fr)
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
MX2009010790A (es) Derivados de heteroarilo biciclico fusionados.
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
WO2004089366A8 (fr) Composes bicycliques comme antagonistes du recepteur nr2b
PH12012500867A1 (en) Ethynyl derivatives
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
DE602004031722D1 (de) Kondensierte bizyklisch substituierte amine als histamin 3 rezeptor liganden
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
JP2015502371A5 (fr)
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina
NO20072060L (no) 2-acylaminotiazolderivater
MX2009002905A (es) Derivados de 3-amino-piridina para el tratamiento de trastornos metabolicos.
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.
ATE479690T1 (de) Thienoä2,3-büpyridin derivate
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06795045

Country of ref document: EP

Kind code of ref document: A2